LabCorp Offers Sera's PreTRM to Assess Preterm Birth Risk
Leading diagnostics testing company LabCorp LH recently announced the availability of Sera Prognostics, Inc.’s PreTRM test at its laboratories in the U.S. It is the only validated blood test offering an early and individualized prediction of preterm birth risk. At the beginning of this year, LabCorp had announced a strategic tie-up with Sera for exclusive U.S. distributorship of the test.
LabCorp has been a lead investor in Sera’s recently closed Series C financing round. The purpose is to continue building clinical evidence to support reimbursement and insurance coverage decisions as well as extend the commercialization of the PreTRM test.
The test was supported by the landmark Proteomic Assessment of Preterm Risk study, evaluating over 5,500 pregnant women over 300 proteins in maternal blood. The study also identified a two-protein signature which was highly predictive of spontaneous preterm birth. The test will help physicians easily predict the risk of preterm birth and intervene earlier to extend the pregnancy toward full term. PreTRM is performed on a standard blood specimen collected during weeks 19 and 20 of pregnancy.
Notably, LabCorp is quite optimistic about its partnership with Sera as the PreTRM test is part of the former’s strategy to deliver world-class diagnostic services. In this regard, we note that preterm birth is the leading cause of infant mortality and morbidity in the U.S. and worldwide.
According to a March of Dimes report, around 400,000 of the 4,000,000 annual births in the U.S. are preterm and up to 50% of women delivering prematurely do not have any identified risk factors for preterm birth. It has also been observed that the children born prematurely can require long term or lifetime care that comes at additional cost.
PreTRM is considered a significant addition to LabCorp’s differentiated women healthcare and reproductive genetics portfolio. The company offers MaterniT 21, a clinically validated non-invasive prenatal test, and the largest network of genetic counselors who can help patients understand genetic test results. LabCorp also offers patient-focused services such as support to obtain insurance pre-authorization before a test is performed and a personalized estimate of the out-of-pocket cost of services before specimen collection by the company.
Share Price Movement
LabCorp has been consistently trading below the Zacks categorized Medical - Dental Supplies industry over the last one month. The stock has gained only 0.6%, compared to 6% of the broader industry. However, the company’s portfolio expansion, acquisitions and collaborations in recent times are expected to boost the stock price.
Zacks Rank & Key Picks
LabCorp currently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the broader medical sector are Luminex Corporation LMNX, Inogen, Inc. INGN and Edwards Lifesciences, Inc. EW. Notably, Luminex and Inogen sport a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 7.1% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 77.8%.
Edwards Lifesciences has an expected long-term adjusted earnings growth of almost 16% (last 3–5 years of actual earnings). The stock added roughly 19.9% over the last three months.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Click for Free Luminex Corporation (LMNX) Stock Analysis Report >>
Click for Free Inogen, Inc (INGN) Stock Analysis Report >>
Click for Free Edwards Lifesciences Corporation (EW) Stock Analysis Report >>
Click for Free Laboratory Corporation of America Holdings (LH) Stock Analysis Report >>
To read this article on Zacks.com click here.
Zacks Investment Research
